Which has higher earnings and valuation, INVA or LGND?

Innoviva has higher revenue and earnings than Ligand Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $420.69M 3.69 $271.17M $6.01 3.50 Ligand Pharmaceuticals $268.09M 21.81 $124.45M $7.37 39.59

Does the media refer more to INVA or LGND?

In the previous week, Ligand Pharmaceuticals had 5 more articles in the media than Innoviva. MarketBeat recorded 13 mentions for Ligand Pharmaceuticals and 8 mentions for Innoviva. Innoviva's average media sentiment score of 1.45 beat Ligand Pharmaceuticals' score of 1.14 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, CLDX or INVA?

Innoviva has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celldex Therapeutics $865K 3,428.88 -$258.76M -$4.26 N/A Innoviva $420.69M 3.69 $271.17M $6.01 3.50

Does the media prefer CLDX or INVA?

In the previous week, Celldex Therapeutics had 9 more articles in the media than Innoviva. MarketBeat recorded 17 mentions for Celldex Therapeutics and 8 mentions for Innoviva. Innoviva's average media sentiment score of 1.45 beat Celldex Therapeutics' score of 0.74 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor INVA or BCRX?

In the previous week, BioCryst Pharmaceuticals had 1 more articles in the media than Innoviva. MarketBeat recorded 9 mentions for BioCryst Pharmaceuticals and 8 mentions for Innoviva. Innoviva's average media sentiment score of 1.45 beat BioCryst Pharmaceuticals' score of 1.13 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ZBIO or INVA?

Innoviva has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zenas BioPharma $10M 200.34 -$377.74M -$8.47 N/A Innoviva $420.69M 3.69 $271.17M $6.01 3.50

Does the media prefer ZBIO or INVA?

In the previous week, Innoviva had 3 more articles in the media than Zenas BioPharma. MarketBeat recorded 8 mentions for Innoviva and 5 mentions for Zenas BioPharma. Innoviva's average media sentiment score of 1.45 beat Zenas BioPharma's score of 1.24 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, INVA or MNKD?

Innoviva has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $420.69M 3.69 $271.17M $6.01 3.50 MannKind $348.97M 3.49 $5.86M -$0.07 N/A

Is INVA or MNKD more profitable?

Innoviva has a net margin of 119.89% compared to MannKind's net margin of -6.63%. Innoviva's return on equity of 33.33% beat MannKind's return on equity. Company Net Margins Return on Equity Return on Assets Innoviva 119.89% 33.33% 22.67% MannKind -6.63% -11.21% -3.92%

Does the media favor INVA or MNKD?

In the previous week, MannKind had 11 more articles in the media than Innoviva. MarketBeat recorded 19 mentions for MannKind and 8 mentions for Innoviva. Innoviva's average media sentiment score of 1.45 beat MannKind's score of 0.89 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 8 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Innoviva (INVA) Competitors

$21.04 -0.18 (-0.86%)

As of 11:03 AM Eastern

Compare

INVA vs. LGND, CLDX, BCRX, ZBIO, and MNKD

Should you buy Innoviva stock or one of its competitors? MarketBeat compares Innoviva with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Innoviva include Ligand Pharmaceuticals (LGND), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Zenas BioPharma (ZBIO), and MannKind (MNKD). These companies are all part of the "biotechnology" industry.

How does Innoviva compare to Ligand Pharmaceuticals?

Innoviva (NASDAQ:INVA) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Innoviva currently has a consensus price target of $36.20, indicating a potential upside of 72.08%. Ligand Pharmaceuticals has a consensus price target of $319.00, indicating a potential upside of 9.32%. Given Innoviva's higher possible upside, analysts clearly believe Innoviva is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, Ligand Pharmaceuticals had 5 more articles in the media than Innoviva. MarketBeat recorded 13 mentions for Ligand Pharmaceuticals and 8 mentions for Innoviva. Innoviva's average media sentiment score of 1.45 beat Ligand Pharmaceuticals' score of 1.14 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

99.1% of Innoviva shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 2.0% of Innoviva shares are held by company insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Innoviva has a net margin of 119.89% compared to Ligand Pharmaceuticals' net margin of 55.95%. Innoviva's return on equity of 33.33% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

Innoviva has higher revenue and earnings than Ligand Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$420.69M	3.69	$271.17M	$6.01	3.50
Ligand Pharmaceuticals	$268.09M	21.81	$124.45M	$7.37	39.59

Summary

Innoviva and Ligand Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Innoviva compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Celldex Therapeutics presently has a consensus price target of $54.62, suggesting a potential upside of 44.53%. Innoviva has a consensus price target of $36.20, suggesting a potential upside of 72.08%. Given Innoviva's higher possible upside, analysts plainly believe Innoviva is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Innoviva has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$865K	3,428.88	-$258.76M	-$4.26	N/A
Innoviva	$420.69M	3.69	$271.17M	$6.01	3.50

In the previous week, Celldex Therapeutics had 9 more articles in the media than Innoviva. MarketBeat recorded 17 mentions for Celldex Therapeutics and 8 mentions for Innoviva. Innoviva's average media sentiment score of 1.45 beat Celldex Therapeutics' score of 0.74 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of Innoviva shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by insiders. Comparatively, 2.0% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Celldex Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Innoviva has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Innoviva has a net margin of 119.89% compared to Celldex Therapeutics' net margin of 0.00%. Innoviva's return on equity of 33.33% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Innoviva	119.89%	33.33%	22.67%

Summary

Innoviva beats Celldex Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Innoviva compare to BioCryst Pharmaceuticals?

Innoviva (NASDAQ:INVA) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Innoviva has a net margin of 119.89% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Innoviva's return on equity of 33.33% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

99.1% of Innoviva shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 2.0% of Innoviva shares are held by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Innoviva has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$420.69M	3.69	$271.17M	$6.01	3.50
BioCryst Pharmaceuticals	$874.84M	2.62	$263.86M	-$1.78	N/A

In the previous week, BioCryst Pharmaceuticals had 1 more articles in the media than Innoviva. MarketBeat recorded 9 mentions for BioCryst Pharmaceuticals and 8 mentions for Innoviva. Innoviva's average media sentiment score of 1.45 beat BioCryst Pharmaceuticals' score of 1.13 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva currently has a consensus price target of $36.20, indicating a potential upside of 72.08%. BioCryst Pharmaceuticals has a consensus price target of $20.80, indicating a potential upside of 130.47%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

Innoviva has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Summary

Innoviva and BioCryst Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Innoviva compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

In the previous week, Innoviva had 3 more articles in the media than Zenas BioPharma. MarketBeat recorded 8 mentions for Innoviva and 5 mentions for Zenas BioPharma. Innoviva's average media sentiment score of 1.45 beat Zenas BioPharma's score of 1.24 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has a net margin of 119.89% compared to Zenas BioPharma's net margin of 0.00%. Innoviva's return on equity of 33.33% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Innoviva	119.89%	33.33%	22.67%

Innoviva has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	200.34	-$377.74M	-$8.47	N/A
Innoviva	$420.69M	3.69	$271.17M	$6.01	3.50

99.1% of Innoviva shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by company insiders. Comparatively, 2.0% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Zenas BioPharma currently has a consensus target price of $44.29, suggesting a potential upside of 39.55%. Innoviva has a consensus target price of $36.20, suggesting a potential upside of 72.08%. Given Innoviva's stronger consensus rating and higher possible upside, analysts plainly believe Innoviva is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Zenas BioPharma has a beta of -0.96, suggesting that its stock price is 196% less volatile than the broader market. Comparatively, Innoviva has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Summary

Innoviva beats Zenas BioPharma on 13 of the 16 factors compared between the two stocks.

How does Innoviva compare to MannKind?

Innoviva (NASDAQ:INVA) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Innoviva has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, MannKind has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market.

Innoviva has a net margin of 119.89% compared to MannKind's net margin of -6.63%. Innoviva's return on equity of 33.33% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
MannKind	-6.63%	-11.21%	-3.92%

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 2.0% of Innoviva shares are owned by company insiders. Comparatively, 2.6% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Innoviva currently has a consensus price target of $36.20, indicating a potential upside of 72.08%. MannKind has a consensus price target of $9.34, indicating a potential upside of 136.85%. Given MannKind's higher possible upside, analysts plainly believe MannKind is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Innoviva has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$420.69M	3.69	$271.17M	$6.01	3.50
MannKind	$348.97M	3.49	$5.86M	-$0.07	N/A

In the previous week, MannKind had 11 more articles in the media than Innoviva. MarketBeat recorded 19 mentions for MannKind and 8 mentions for Innoviva. Innoviva's average media sentiment score of 1.45 beat MannKind's score of 0.89 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	8 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Innoviva beats MannKind on 11 of the 16 factors compared between the two stocks.

Get Innoviva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INVA vs. The Competition

Export

Metric	Innoviva	Large Cap Pharma Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.55B	$327.78B	$6.86B	$12.37B
Dividend Yield	N/A	2.58%	2.65%	10.11%
P/E Ratio	3.50	29.97	27.45	23.66
Price / Sales	3.69	4.99	495.52	78.38
Price / Cash	4.30	14.49	51.74	58.30
Price / Book	1.34	8.18	9.91	5.85
Net Income	$271.17M	$11.61B	$3.61B	$336.64M
7 Day Performance	-1.88%	-0.92%	-0.29%	0.02%
1 Month Performance	-7.37%	-0.12%	-3.96%	-5.24%
1 Year Performance	15.78%	34.73%	22.83%	17.56%

Innoviva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INVA Innoviva	3.1718 of 5 stars	$21.04 -0.9%	$36.20 +72.1%	+15.1%	$1.55B	$420.69M	3.50	100	Positive News Upcoming Earnings
LGND Ligand Pharmaceuticals	3.7774 of 5 stars	$300.53 -0.5%	$319.00 +6.1%	+119.1%	$6.02B	$268.09M	40.78	80	News Coverage Positive News Upcoming Earnings
CLDX Celldex Therapeutics	2.8824 of 5 stars	$35.28 -0.4%	$52.77 +49.6%	+68.7%	$2.77B	$1.54M	N/A	150	Upcoming Earnings Analyst Forecast
BCRX BioCryst Pharmaceuticals	3.6002 of 5 stars	$9.34 -0.4%	$20.80 +122.7%	+12.4%	$2.37B	$874.84M	N/A	530	Positive News Upcoming Earnings Short Interest Decrease
ZBIO Zenas BioPharma	3.9237 of 5 stars	$30.39 -1.9%	$44.29 +45.7%	+104.9%	$1.92B	$10M	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INVA) was last updated on 7/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Innoviva (INVA) Competitors

INVA vs. LGND, CLDX, BCRX, ZBIO, and MNKD

How does Innoviva compare to Ligand Pharmaceuticals?

Summary

How does Innoviva compare to Celldex Therapeutics?

Summary

How does Innoviva compare to BioCryst Pharmaceuticals?

Summary

How does Innoviva compare to Zenas BioPharma?

Summary

How does Innoviva compare to MannKind?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA vs. The Competition

Innoviva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Innoviva (INVA) Competitors

INVA vs. LGND, CLDX, BCRX, ZBIO, and MNKD

How does Innoviva compare to Ligand Pharmaceuticals?

Do analysts prefer INVA or LGND?

Does the media refer more to INVA or LGND?

Which has more risk & volatility, INVA or LGND?

Do institutionals & insiders believe in INVA or LGND?

Is INVA or LGND more profitable?

Which has higher earnings and valuation, INVA or LGND?

Summary

How does Innoviva compare to Celldex Therapeutics?

Do analysts recommend CLDX or INVA?

Which has better earnings & valuation, CLDX or INVA?

Does the media prefer CLDX or INVA?

Do institutionals and insiders hold more shares of CLDX or INVA?

Which has more volatility and risk, CLDX or INVA?

Is CLDX or INVA more profitable?

Summary

How does Innoviva compare to BioCryst Pharmaceuticals?

Is INVA or BCRX more profitable?

Do insiders & institutionals believe in INVA or BCRX?

Which has stronger valuation & earnings, INVA or BCRX?

Does the media favor INVA or BCRX?

Do analysts rate INVA or BCRX?

Which has more risk & volatility, INVA or BCRX?

Summary

How does Innoviva compare to Zenas BioPharma?

Does the media prefer ZBIO or INVA?

Is ZBIO or INVA more profitable?

Which has stronger earnings & valuation, ZBIO or INVA?

Do institutionals and insiders hold more shares of ZBIO or INVA?

Do analysts recommend ZBIO or INVA?

Which has more volatility and risk, ZBIO or INVA?

Summary

How does Innoviva compare to MannKind?

Which has more volatility and risk, INVA or MNKD?

Is INVA or MNKD more profitable?

Do institutionals & insiders believe in INVA or MNKD?

Do analysts rate INVA or MNKD?

Which has higher valuation and earnings, INVA or MNKD?

Does the media favor INVA or MNKD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA vs. The Competition

Innoviva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools